FBB Biomed
Biotech developing RUO liquid biopsy tests for neurologic diseases via blood draws.
Website: https://www.fbbbio.com/
Cover Block
PUBLIC
| Field | Value |
|---|---|
| Name | FBB Biomed |
| Tagline | Biotech developing RUO liquid biopsy tests for neurologic diseases via blood draws |
| Headquarters | Iowa City, IA, USA |
| Founded | 2019 |
| Stage | Seed |
| Business Model | B2B |
| Industry | Healthtech |
| Technology | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Funding Label | Seed (total disclosed approximately $326,000) |
Links
PUBLIC
- Website: https://www.fbbbio.com/
- LinkedIn: https://www.linkedin.com/company/fbb-biomed
Executive Summary
PUBLIC
FBB Biomed is an Iowa City based biotech building Research Use Only (RUO) liquid biopsy tests for neurologic disease, a category where the standard diagnostic path still relies on imaging, lumbar puncture, or clinical observation rather than a routine blood draw. The company was founded in 2019 and emerged from a research program initially focused on RNA biomarkers for predicting COVID-19 disease severity [GenomeWeb] before redirecting its platform toward neurologic indications including Parkinson's, Alzheimer's, multiple sclerosis, ALS, depression, schizophrenia, and long COVID [University of Iowa Research Park]. Its core product is described on the company website as the first RUO liquid biopsy test dedicated to neurologic diseases, powered by a platform the company calls Personalized Genomic Intelligence that incorporates a virology dataset [FBB Biomed website]. Chief Executive Officer Howard Urnovitz, a University of Michigan trained PhD with a long publication record in RNA virology, leads the company [Crunchbase] [ResearchGate]. Disclosed funding to date totals roughly $326,000 from a 2020 seed filing [Tracxn], supplemented by small non-dilutive grants from the Iowa Innovation Challenge and the University of Iowa's John Pappajohn Entrepreneurial Center [Clayandmilk] [JPEC]. The next 12 to 18 months should clarify whether the December 2024 move from research into commercial RUO testing through a CLIA and CAP certified lab partner produces measurable clinician adoption and whether the company can attract institutional capital beyond its current university-anchored backers.
Data Accuracy: GREEN -- Confirmed across Crunchbase, PitchBook, Tracxn, GenomeWeb, and the University of Iowa Research Park.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | B2B (laboratory services for clinicians and research partners) |
| Industry / Vertical | Healthtech, in vitro diagnostics |
| Technology Type | Biotech / Life Sciences (RNA biomarkers, NGS based liquid biopsy) |
| Geography | North America (Iowa City, IA) |
| Growth Profile | Venture Scale |
| Founding Team | CEO Howard Urnovitz, PhD (additional cofounders not publicly disclosed) |
| Funding | Approximately $326,000 disclosed seed plus small grants |
Company Overview
PUBLIC
FBB Biomed, Inc. is a privately held biotech incorporated in Iowa and operating out of the University of Iowa Research Park in Iowa City [University of Iowa Research Park]. PitchBook lists 2019 as the founding year [PitchBook], and the company describes itself as harnessing advances in genetics, bioinformatics, and RNA virology to develop approaches for inflammatory and neurologic disease [Crunchbase]. The about page on the company website notes Michigan roots alongside its Iowa operations and lists working relationships with the University of Iowa, Iowa State University, the Iowa Economic Development Authority, and the University of Michigan [FBB Biomed website].
The company's first publicly described product was a blood test for RNA biomarkers intended to predict COVID-19 disease severity, with a Gust profile from the early period stating that the prototype was being prepared for clinical trials with the goal of an FDA Emergency Use Authorization [Gust] [GenomeWeb]. That early focus did not become a commercial diagnostic, and the platform was repositioned toward neurologic indications. The first disclosed financing was an August 2020 seed filing for $326,000 reported across six investors in an SEC Form D entry [whoisraisingmoney.com] [Tracxn]. The company subsequently won the 2021 Iowa Innovation Challenge with a $20,000 award [Clayandmilk] and took prizes in the 2022 and 2023 graduate, faculty, and staff tracks of the John Pappajohn Entrepreneurial Center startup incubator [JPEC, July 2022] [JPEC, July 2023].
The most recent public milestone is a December 2024 note on the company website indicating that FBB moved from research into a commercial posture by signing an agreement with a CLIA and CAP certified laboratory to begin offering RUO tests [FBB Biomed website]. A separate University of Iowa Research Park profile references an agreement with Verici Dx plc covering laboratory services for RUO tests aimed at clinicians seeking insight into Parkinson's, Alzheimer's, multiple sclerosis, ALS, depression, schizophrenia, and long COVID [University of Iowa Research Park]. The two notes appear to describe the same commercial transition, although the public record does not yet include independent press confirmation of the Verici Dx agreement.
Data Accuracy: GREEN -- Confirmed across Crunchbase, PitchBook, Tracxn, the University of Iowa Research Park, and the company's own site.
Product and Technology
MIXED
The core product, as described on the company website, is a Research Use Only liquid biopsy test that uses a standard blood draw to capture biomarkers mapping an individual's metabolic dysfunction [PUBLIC] [FBB Biomed website]. The company frames this as the first RUO liquid biopsy test dedicated to neurologic diseases [PUBLIC] [FBB Biomed website]. The "first" designation is a company claim and is not corroborated by a third-party report in the captured sources, so investors should treat it as a marketing positioning rather than an externally verified fact.
The underlying platform is described by the company as Personalized Genomic Intelligence, an analytical layer that incorporates an expanded virology dataset reaching back into what the company calls the ancestral past, a reference to endogenous retroviral and other RNA elements long studied by CEO Howard Urnovitz [PUBLIC] [FBB Biomed website] [ResearchGate]. The science page draws an analogy to having "the manual" for an individual sample, with the stated utility of placing a sample into a disease risk group [PUBLIC] [FBB Biomed website]. A third-party company directory describes the test as providing neurologists with a liquid biopsy for brain diseases [PUBLIC] [ensun.io]. The product workflow page indicates that participants have blood drawn through a research partner clinic (the MaxWell Clinic is named on the research participants page) and that the lab processes the sample [PUBLIC] [FBB Biomed website].
On the operational side, the partners page states that the test runs on standard next-generation sequencing instruments without new hardware, which is positioned as a way for partner labs to use existing NGS capacity [PUBLIC] [FBB Biomed website]. The December 2024 note about a CLIA and CAP certified lab agreement, together with the University of Iowa Research Park reference to Verici Dx plc as a laboratory services partner, suggests that wet-lab processing for the commercial RUO offering is being outsourced rather than performed in-house [PUBLIC] [FBB Biomed website] [University of Iowa Research Park]. Because the test is designated Research Use Only, it is not cleared by the FDA as an in vitro diagnostic and cannot be marketed for clinical decision making in the United States; that is a regulatory feature of the RUO category rather than a finding specific to FBB.
Data Accuracy: YELLOW -- Product description is fully sourced to the company site and partner profile; the "first in category" claim and the technical performance of the assay are not independently verified in the captured public record.
Market Research and Opportunity
PUBLIC
Neurologic disease is one of the few large diagnostic categories where blood-based molecular testing is still early, which is the structural reason a small company can credibly aim at it. Alzheimer's, Parkinson's, multiple sclerosis, and ALS together affect tens of millions of patients globally, and the diagnostic standard of care has historically depended on clinical assessment, imaging, and in some cases cerebrospinal fluid analysis. The arrival of disease-modifying therapies for Alzheimer's over the last several years has pulled blood-based biomarker testing from a research curiosity toward a practical clinical workflow, and that shift in physician behavior is the demand backdrop for any new entrant in neuro liquid biopsy.
The captured research does not include a named third-party TAM, SAM, or SOM figure specific to neurologic liquid biopsy, so this report does not assert a market size number. What the cited evidence does establish is the indication breadth FBB is targeting: Parkinson's, Alzheimer's, multiple sclerosis, ALS, depression, schizophrenia, and long COVID [University of Iowa Research Park]. That indication list spans both classic neurodegeneration and neuropsychiatric conditions, which is a wider scope than most single-assay competitors pursue and implies a platform play rather than a single-disease bet.
Demand drivers visible in the cited material are threefold. First, the move from research into a commercial RUO offering through a CLIA and CAP certified lab partner in December 2024 indicates that the company sees clinician demand for advanced insights as immediate rather than hypothetical [FBB Biomed website]. Second, the partners page positions the assay to run on standard NGS sequencers, which lowers the activation cost for any reference lab considering adding the test [FBB Biomed website]. Third, the Iowa university ecosystem (University of Iowa, Iowa State, the John Pappajohn Entrepreneurial Center, and the University of Iowa Research Park) provides clinical research access that an unaffiliated startup of this size would struggle to reproduce [University of Iowa Research Park] [JPEC, July 2023].
Adjacent and substitute markets matter for framing. Cerebrospinal fluid biomarker panels, PET imaging for amyloid and tau, plasma p-tau assays, and emerging digital cognitive assessments all compete for the same clinician decision moment. Regulatory posture is the gating macro variable: an RUO designation is a permitted commercial path for laboratory research use, but reimbursement, payer coverage, and any future move toward an FDA cleared in vitro diagnostic would each require additional capital, validation studies, and time. None of those steps are publicly disclosed as in progress.
| Sizing claim | Value | Source |
|---|---|---|
| Disclosed seed financing (2020) | approximately $326,000 | [Tracxn] |
| Indications publicly targeted by RUO test | 7 (Parkinson's, Alzheimer's, MS, ALS, depression, schizophrenia, long COVID) | [University of Iowa Research Park] |
The takeaway is that the captured public record supports a credible thesis on category timing and indication breadth, but it does not yet contain a third-party market size figure for neurologic liquid biopsy specifically. Investors evaluating the opportunity will need to triangulate from analogous oncology liquid biopsy reports and from Alzheimer's blood biomarker coverage decisions rather than from a FBB-specific market study.
Data Accuracy: YELLOW -- Indication scope and commercial transition are confirmed by the company site and the University of Iowa Research Park; no third-party TAM figure is available in the captured sources.
Competitive Landscape
MIXED
FBB Biomed is positioned as a small, university-anchored entrant in a neurologic diagnostics category where the most visible activity sits with larger plasma biomarker programs and with reference laboratories rather than with venture-scale startups. The structured facts include no named competitors, so this section is written as prose rather than as a comparison table.
The segment map can be divided into three groups. The first group is the plasma biomarker incumbents and large diagnostic laboratories that have built Alzheimer's-focused blood tests around p-tau and related markers; these players bring scale, sales coverage to neurology clinics, and existing payer relationships, but their assays are typically focused on a single indication family. The second group is academic and translational programs developing RNA, exosome, and cell-free nucleic acid signatures for neurodegeneration, which are closer to FBB's technical posture and which compete for the same clinical research collaborations rather than for immediate commercial revenue. The third group is the platform companies offering laboratory services on standard NGS infrastructure; FBB's partners page explicitly courts this group as a channel rather than treating them as competitors [FBB Biomed website].
Where FBB has a defensible edge today is the combination of a wide indication scope (seven named conditions including neuropsychiatric and post-viral targets) [University of Iowa Research Park] and a CEO whose published research record in RNA virology is unusual for a company of this size [ResearchGate]. The university affiliations provide patient access and credibility that would be expensive to replicate. That edge is durable to the extent the underlying biomarker signatures are proprietary and protected, and perishable to the extent that larger plasma assay programs can extend into adjacent indications faster than FBB can validate them.
Where FBB is most exposed is capital and commercial reach. With roughly $326,000 in disclosed seed funding [Tracxn] and a reliance on a third-party CLIA and CAP certified lab for commercial processing [FBB Biomed website], FBB cannot match the field force, payer engagement, or trial spending of a national reference lab or a publicly traded diagnostics company. The most plausible 18-month scenario is bifurcated: FBB wins if the CLIA and CAP lab partnership generates clinician-driven RUO test orders that produce a publishable real-world evidence dataset, which in turn becomes the basis for an institutional Series A; FBB loses ground if a larger plasma biomarker program publishes a comparable multi-indication panel before FBB's own validation work reaches peer-reviewed publication, in which case the "first RUO liquid biopsy for neurologic diseases" positioning becomes harder to defend.
Data Accuracy: ORANGE -- No competitors named in the structured facts; competitive framing is inferred from the cited indication scope and the public record on adjacent neuro-diagnostic categories.
Opportunity
PUBLIC
If FBB Biomed executes against the indication list it has published, the prize is a platform position in blood-based neurologic diagnostics rather than a single-test business.
The headline opportunity. The single largest outcome FBB could plausibly become is the default RNA-based liquid biopsy platform that neurologists and neuro-research centers use to triage patients across multiple neurodegenerative and neuropsychiatric indications. The cited evidence makes that outcome reachable rather than aspirational for three specific reasons: the assay is designed to run on standard NGS instruments already deployed in reference labs [FBB Biomed website], the commercial channel is being established through a CLIA and CAP certified lab partner rather than requiring FBB to build its own clinical lab [FBB Biomed website], and the indication scope spans seven conditions, which means a single platform sale into a reference lab can be amortized across multiple test orders [University of Iowa Research Park]. The economic shape of that outcome is closer to a specialty molecular diagnostics platform than to a single-assay company.
Growth scenarios.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Reference lab embed | The CLIA and CAP partner becomes a high-volume processing channel and FBB licenses the assay to additional reference labs | Published clinical utility data from the partner lab's first cohort [FBB Biomed website] | The assay is designed to fit existing NGS workflows with no new hardware, lowering activation cost for additional labs [FBB Biomed website] |
| Pharma research services | FBB sells access to its Personalized Genomic Intelligence platform to pharmaceutical sponsors running neurology trials as a patient stratification tool | A named pharma collaboration in any of the seven targeted indications [University of Iowa Research Park] | The indication list overlaps directly with active pharma development in Alzheimer's, Parkinson's, and ALS |
| Academic consortium standard | FBB becomes the preferred RNA biomarker platform within a university research consortium centered on Iowa and Michigan partners | Multi-site validation study published by University of Iowa or Iowa State collaborators [FBB Biomed website] | The company already cites working relationships with the University of Iowa, Iowa State, IEDA, and the University of Michigan [FBB Biomed website] |
What compounding looks like. The flywheel for a multi-indication RUO platform compounds through data. Each test processed by the CLIA and CAP partner adds a labeled sample to the Personalized Genomic Intelligence dataset, which in turn improves the risk-group assignments the science page describes [FBB Biomed website]. A larger and more diverse reference dataset is the moat that protects a small company against a larger plasma biomarker program with more capital, because the dataset is what produces the multi-indication breadth that single-disease assays cannot match. Distribution compounds in parallel: every reference lab that adopts the assay on its existing NGS instruments becomes a channel for the next indication FBB validates, without the company needing to add field sales headcount.
The size of the win. No third-party TAM figure for neurologic liquid biopsy is present in the captured sources, so this report does not put a dollar value on the category. What the cited evidence does support is a comparison frame: specialty molecular diagnostics companies that establish a defensible platform position in a single therapeutic area have historically been valued at a meaningful multiple of revenue once recurring lab volume materializes, and the move from research to a commercial RUO offering through a certified lab partner is the precondition for that revenue to begin accruing [FBB Biomed website]. Treat any specific dollar projection as a scenario rather than a forecast; the conditions for upside are clinician adoption, published clinical utility data, and an institutional Series A that funds the validation work needed to extend beyond the current RUO designation.
Data Accuracy: YELLOW -- Scenarios are anchored to confirmed product, partnership, and indication facts; no third-party TAM or comparable valuation figure is present in the captured sources.
Sources
PUBLIC
[FBB Biomed] FBB Biomed - one life, one test | https://www.fbbbio.com/
[FBB Biomed] About | FBB - Main | https://www.fbbbio.com/about
[FBB Biomed] Product | FBB - Main | https://www.fbbbio.com/product
[FBB Biomed] Science | FBB - Main | https://www.fbbbio.com/science
[FBB Biomed] Partners | FBB - Main | https://www.fbbbio.com/partners
[FBB Biomed] Research Participants | FBB - Main | https://www.fbbbio.com/research-participants
[PitchBook] FBB Biomed 2025 Company Profile: Valuation, Funding & Investors | https://pitchbook.com/profiles/company/433585-90
[Gust] FBB Biomed, Inc. Iowa City, IA, USA Startup | https://gust.com/companies/fbb-biomed
[University of Iowa Research Park] FBB Biomed | University of Iowa Research Park | https://researchpark.uiowa.edu/about-uirp/our-companies/fbb-biomed
[Crunchbase] FBB Biomed - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/fbb-biomed
[Crunchbase] Howard Urnovitz - Crunchbase Person Profile | https://www.crunchbase.com/person/howard-urnovitz
[CB Insights] FBB Biomed Stock Price, Funding, Valuation, Revenue & Financial Statements | https://www.cbinsights.com/company/fbb-biomed/financials
[Tracxn] FBB Biomed - 2026 Company Profile & Team | https://tracxn.com/d/companies/fbb-biomed/__-3w98Nf2vEzw1X2kedsljIbIHtjU0SgwCrCFor5HmD8
[GenomeWeb] Iowa Startup FBB Biomed Pursues RNA Blood Test to Predict COVID-19 Disease Severity | https://www.genomeweb.com/infectious-disease/iowa-startup-fbb-biomed-pursues-rna-blood-test-predict-covid-19-disease-severity
[JPEC, July 2022] FBB BioMed Wins Graduate/Faculty Track Pitch Competition | https://iowajpec.org/news/2022/07/fbb-biomed-wins-graduatefaculty-track-pitch-competition
[JPEC, July 2023] FBB Biomed Wins Iowa JPEC Grad/Faculty/Staff Startup Incubator Summer Track | https://iowajpec.org/news/2023/07/fbb-biomed-wins-iowa-jpec-gradfacultystaff-startup-incubator-summer-track
[Clayandmilk, November 2021] Iowa Innovation Challenge Announces Winners, Awards 75k in Prizes | https://clayandmilk.com/2021/11/24/iowa-innovation-challenge-announces-winners-awards-75k-in-prizes/
[ResearchGate] Howard Urnovitz | CEO | Doctor of Philosophy | Research profile | https://www.researchgate.net/profile/Howard-Urnovitz
[whoisraisingmoney.com] FBB Biomed, Inc. SEC filing of fundraising | https://www.whoisraisingmoney.com/fbb-biomed-inc
[ensun.io] FBB Biomed Company profile | https://ensun.io/company/fbb-biomed-649ee148d5c009ba944e795f
Articles about FBB Biomed
- FBB Biomed Wants a Single Blood Draw to Read the Brain's Earliest Warning Signs — The Iowa City startup is offering Research Use Only liquid biopsies for Parkinson's, Alzheimer's, ALS and long COVID through a CLIA-certified lab partner.